Placebo to NT201

DRUG3 trials

Sponsors

Merz Pharmaceuticals GmbH, Centre Hospitalier Universitaire De Nantes, Falck clinic

Conditions

Pediatric lower limb (LL) spasticity (SP) caused by cerebral palsy (CP)Severe primary dysmenorrheaWrinklesfine lines

Phase 2

Satisfaction study of split doses botulinum toxin with double frequency

RecruitingCTIS2025-520915-14-00

Falck clinicfine lines, Wrinkles

Start: 2023-01-12Target: 52Updated: 2025-06-10

Phase 3

A prospective, randomized, double-blind, placebo-controlled, two-stage, multicenter study with an open-label extension period to investigate the efficacy and safety of NT 201 in the treatment of lower limb spasticity in children and adolescents with cerebral palsy

CompletedCTIS2023-503420-19-00

Merz Pharmaceuticals GmbHPediatric lower limb (LL) spasticity (SP) caused by cerebral palsy (CP)

Start: 2022-10-12End: 2025-03-04Target: 25Updated: 2024-12-20

Evaluation of the Analgesic Effect of Intramyometrial Botulinum Toxin Injection via Hysteroscopy in Severe Primary Dysmenorrhea: A Prospective, Multicenter, Double-Blind, Randomized Placebo-Controlled Study. HYSTEROXINE Study

Not yet recruitingCTIS2025-520638-53-00

Centre Hospitalier Universitaire De NantesSevere primary dysmenorrhea

Target: 222Updated: 2025-09-19